Novo Integrated Sciences Inc (NVOS) News

Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness...

Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement

Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full with Cash Proceeds from the Streeterville Note Novo...

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as...

Form 8-K - Current report

Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International, LLC (“CCI”), a Novo wholly-owned...

Form 8-K - Current report

Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note

The Waiver Exempts any determination of non-compliance associated to Nasdaq’s Minimum Bid Price Requirement Rule Novo Integrated Sciences, Inc...

Form 8-K - Current report

Novo Integrated Sciences Appoints New President

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today Mr. Robert Oliva has been appointed as the Company’s new...

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness...

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB